Using targeted radiation and immunotherapy to treat certain cancers
Official title: Targeted radiation and immunocytokine therapy for CEA positive malignancies
Funded at Beckman Research Institute/city of Hope · NIH-10932893 · Data updated 2026-11-12
This study is looking at a new way to treat certain cancers by using a mix of targeted radiation and a special immune therapy to help your body fight the tumor better, and it's for patients whose cancers have a specific marker called CEA.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beckman Research Institute/city of Hope NIH-funded |
| Lab location | 1 site (Duarte, United States) |
| Project start | September 21, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $642,450 |
| NIH project number | 5R01CA283603-02 |
| Project ID | NIH-10932893 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with cancers that express carcinoembryonic antigen, such as colon or breast cancer.
✕Less likely to help
Patients with cancers that do not express carcinoembryonic antigen or those who are not eligible for radiation therapy may not benefit from this research.
What this research studies
This research investigates a combination of image-guided radiotherapy and targeted immunotherapy to improve treatment outcomes for cancers that express the carcinoembryonic antigen (CEA). The approach aims to modify the tumor microenvironment to make tumors more susceptible to immune attack. Patients will receive targeted radiation followed by immunocytokine therapy, which is designed to enhance the immune response against the tumor. The research includes clinical trials that will assess the effectiveness of this treatment in increasing immune cell infiltration into tumors.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with CEA-positive malignancies, potentially improving survival rates.
How similar studies have gone: Previous studies have shown promise in using targeted radiation combined with immunotherapy, suggesting that this approach could be effective.
Where this research is happening
-
Beckman Research Institute/city of Hope
Duarte, United States Active
Researchers
- Principal investigator: Shively, John Ernest — Beckman Research Institute/city of Hope
- Study coordinator: Shively, John Ernest
Related research
Other NIH-funded projects on the same topics.
-
Targeting the protein-assembly that drives AML growth
Aiming to slow or stop acute myeloid leukemia by blocking how cancer cells make proteins.
-
Metformin for reversing accelerated aging in young adults with metabolic health issues
A practical plan to use metformin to help 18- to 35-year-olds with insulin resistance improve metabolic health and slow aging.
-
PIN1-targeted therapy for pancreatic cancer
A team is developing new PIN1 inhibitors to treat pancreatic cancer that tends to resist current therapies.
-
DNA mismatch repair defects and anti-tumor immunity in cancer
Researchers are studying how defects in a DNA repair system affect the body’s immune response to tumors, to improve cancer treatments that use the immune system.
-
Understanding how skin cancer-associated fibroblasts affect immune detection in early mycosis fungoides
This grant investigates how certain skin cells in early mycosis fungoides might help the cancer hide from the immune system, with findings aiming to improve future patient care.
-
Small-molecule and biologic treatments for glioblastoma using targeted brain delivery
A new approach aims to use FPS-ZM1 to shrink brain swelling and support immunotherapy for glioblastoma, potentially helping patients recover after surgery.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.